FDA Approved: LYRICA — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for LYRICA (pregabalin) submitted by Parke-Davis (Pfizer) to update the labeling with expanded or new indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy
• Epilepsy
• Fibromyalgia
• Generalized Anxiety Disorder
• Postherpetic Neuralgia
• Spinal Cord Injury Pain

Drugs mentioned

• Lyrica (Pregabalin)

Snippet

SUPPL AP for LYRICA (PREGABALIN)